Research and Clinical Trials

Brief Description  
The Phase II of this study aims to evaluate the efficacy and safety of clofarabine in combination with cytarabine for the treatment of relapse refractory leukemia (AML, ALL, ambiguous lineage).
Who may be Eligible  
Patients ages 1 to less than or equal to 30 years, diagnosed with relapsed or refractory leukemia (ALL, AML or ambiguous lineage).
Pediatric Cancer
IRB Number  
Principal Investigator  
Kaplan, Joel

For More Information, Contact  Beatriz  G, Perez-Li
Phone:  (704) 446-5285  Fax:  (704) 355-1188  
Address:1025 Morehead Medical Drive Charlotte, NC